Article
Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial.
Blood - 1 Jun 2001
Karp J E, Lancet J E, Kaufmann S H, End D W, Wright J J, Bol K, Horak I, Tidwell M L, Liesveld J, Kottke T J, Ange D, Buddharaju L, Gojo I, Highsmith W E, Belly R T, Hohl R J, Rybak M E, Thibault A, Rosenblatt J
Abstract excerpt
R115777 is a nonpeptidomimetic enzyme-specific inhibitor of farnesyl protein transferase (FT) that was developed as a potential inhibitor of Ras protein signaling, with antitumor activity in preclinical models. This study was a phase 1 trial of orally administered R115777 in 35 adults with poor-risk acute leukemias. Cohorts of patients received R115777 at doses ranging from 100 mg twice daily (bid) to 1200 mg bid...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.